Duopharma Biotech Bhd 2025 IR

The report highlights Duopharma Biotech Berhad's financial and sustainability performance for the fiscal year 2025. The company achieved a 14.5% increase in revenue to RM931.69 million and a 43.6% surge in profit before tax to RM114.91 million. Key achievements include obtaining the first-ever halal certification from JAKIM for a biosimilar erythropoietin (ERYSAA_x0000_) and receiving EU GMP certification for its highly potent active pharmaceutical ingredients (HAPI) plant. On the environmental front, the company reduced its Scope 1 and 2 greenhouse gas emissions intensity by 14% year-on-year and generated 3.2 GWh of solar power across its manufacturing sites.

Company: Duopharma Biotech Bhd

Sector: Health Care

Country: Malaysia

Year: 2025

Type: IR

Pages: 272

Back to company

Duopharma Biotech Bhd

Duopharma Biotech Bhd 2025 Integrated Annual Report

Integrated Annual Report

The report highlights Duopharma Biotech Berhad's financial and sustainability performance for the fiscal year 2025. The company achieved a 14.5% increase in revenue to RM931.69 million and a 43.6% surge in profit before tax to RM114.91 million. Key achievements include obtaining the first-ever halal certification from JAKIM for a biosimilar erythropoietin (ERYSAA_x0000_) and receiving EU GMP certification for its highly potent active pharmaceutical ingredients (HAPI) plant. On the environmental front, the company reduced its Scope 1 and 2 greenhouse gas emissions intensity by 14% year-on-year and generated 3.2 GWh of solar power across its manufacturing sites.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2025

Reporting Period

Jan 1, 2025 - Dec 31, 2025

Fiscal Year

2025

Type

Integrated Report

Language

English

Pages

 

File Size

 

Standards & Assurance

Reporting Standards

Materiality Assessment

Assurance

Assurance Provider

Assurance Standard

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Scope 3:

Energy Consumption

Water Consumption

Total Waste

Women on Board

Women in Management

Workplace Fatalities

Net Zero Target

Employees

Duopharma Biotech Bhd 2025 Integrated Report - Free PDF